VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
TEL AVIV, Israel, June 04, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating […]